About Freeline
Freeline is a company based in Stevenage (United Kingdom) founded in 2015 was acquired by Syncona in November 2023. Freeline has raised $273.69 million across 6 funding rounds from investors including Syncona, TD Securities and UCL Technology Fund. The company has 152 employees as of December 31, 2020. Freeline has completed 1 acquisition, including SwanBio Therapeutics. Freeline offers products and services including FLT201, Gene Therapy for Parkinson's, and Gene Therapy for AMN. Freeline operates in a competitive market with competitors including BridgeBio, Spark Therapeutics, Alnylam, ATAI and Insitro, among others.
- Headquarter Stevenage, United Kingdom
- Employees 152 as on 31 Dec, 2020
- Stage Public
-
Sectors
Healthcare
-
Email
Locked
-
Phone
Locked
-
Website
Locked
-
Social
Locked
- Legal Name Freeline Therapeutics Limited
- Date of Incorporation 19 Mar, 2015
- Jurisdiction STEVENAGE, HERTFORDSHIRE, ENGLAND
-
Annual Revenue
$435.87 K (USD)0as on Dec 31, 2018
-
Net Profit
-$38.39 M (USD)-88as on Dec 31, 2018
-
EBITDA
Not available
-
Total Equity Funding
$273.69 M (USD)
in 6 rounds
-
Latest Funding Round
$125.51 M (USD), Post-IPO
Aug 14, 2020
-
Investors
Syncona
& 7 more
-
Employee Count
152
as on Dec 31, 2020
- Investments & Acquisitions
-
Acquired by
Syncona
(Nov 22, 2023)
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Products & Services of Freeline
Freeline offers a comprehensive portfolio of products and services, including FLT201, Gene Therapy for Parkinson's, and Gene Therapy for AMN.
Gene therapy candidate targeting Gaucher Disease through clinical trials.
Treatment aimed at modifying Parkinson's Disease progression.
First-in-class therapy for adrenomyeloneuropathy conditions.
People of Freeline
Unlock access to complete
Unlock access to complete
Funding Insights of Freeline
Freeline has successfully raised a total of $273.69M across 6 strategic funding rounds. The most recent funding activity was a Post-IPO round of $125.51 million completed in August 2020. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
Investors in Freeline
Freeline has secured backing from 8 investors, including venture fund and institutional investors. Prominent investors backing the company include Syncona, TD Securities and UCL Technology Fund.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Private equity and venture capital fund focused on the healthcare sector
|
Locked | Locked | Locked | |
|
-
|
Locked | Locked | Locked | |
|
Healthcare investments are managed via private equity by Syncona.
|
Locked | Locked | Locked |
Investor details for Freeline
Investor domains, locations, round participation, and complete history require an active premium plan.
- Investor domains
- Investor locations
- Funding rounds
- Participation history
Verified entity values are shown only after access is granted.
Investments & Acquisitions by Freeline
Freeline has strategically engaged in corporate development activities, having acquired 1 company. Notable acquisitions include SwanBio Therapeutics.
Investment portfolio details for Freeline
Portfolio company identities, transaction dates, round details, and investment values require an active premium plan.
- Portfolio identities
- Transaction dates
- Round details
- Investment values
Verified entity values are shown only after access is granted.
| Company Name | Description | Domain | Location | Founded Year | Amount |
|---|---|---|---|---|---|
|
AAV-based gene therapy for neurological diseases is provided.
|
Locked | Locked | 2017 | Locked |
Complete acquisition details for Freeline
Transaction dates, acquired stakes, disclosed values, domains, and locations require an active premium plan.
- Transaction dates
- Acquired stakes
- Disclosed values
- Domains and locations
Verified entity values are shown only after access is granted.
Financial Statements - Freeline
Detailed financials for Freeline
Historical revenue, profit, statement rows, ratios, and trend charts require an active premium plan.
- Historical revenue
- Profit trends
- Statement rows
- Financial ratios
Verified entity values are shown only after access is granted.
Freeline Comparisons
Peer comparison for Freeline
Named peer metrics, headcount, funding, location, and side-by-side benchmarks require an active premium plan.
- Named peers
- Headcount comparison
- Funding comparison
- Operating benchmarks
Verified entity values are shown only after access is granted.
Competitors of Freeline
Freeline operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as BridgeBio, Spark Therapeutics, Alnylam, ATAI and Insitro, among others.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| Locked | Locked | Locked |
Therapeutics for genetic diseases are developed through targeted interventions.
|
|
| Locked | Locked | Locked |
Gene therapies for rare diseases including retinal dystrophies are developed.
|
|
| Locked | Locked | Locked |
RNA interference-based therapeutics are developed for multiple disorders.
|
|
| Locked | Locked | Locked |
A biopharmaceutical company accelerating innovative mental health treatments.
|
|
| Locked | Locked | Locked |
An AI-enabled platform is developed for infectious disease treatment.
|
|
| Locked | Locked | Locked |
Therapeutics for rare and ultra-rare metabolic diseases are developed.
|
Detailed competitors of Freeline
Competitor domains, locations, full profiles, and operating metrics require an active premium plan.
- Domains and locations
- Full company profiles
- Operating metrics
- Competitive positioning
Verified entity values are shown only after access is granted.
Latest news on Freeline
Complete news archive for Freeline
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Freeline
Freeline was founded in 2015.
Freeline is headquartered in Stevenage, United Kingdom. It is registered at Stevenage, Hertfordshire, United Kingdom.
Michael Parini is the current CEO of Freeline.
Freeline is a funded company, having raised a total of $273.69M across 6 funding rounds to date.
As of Dec 31, 2020, the latest employee count at Freeline is 152.
Annual revenue of Freeline is $435.87K as on Dec 31, 2018.
Freeline was founded in 2015 in Stevenage, United Kingdom, as a biotechnology company focused on gene therapy. A platform is offered to deliver therapeutic genes to the liver, enabling secretion of proteins for patients with hemophilia (FLT180a) and Fabry disease (FLT190). Lysosomal storage disorders are diagnosed, and clinical trial solutions are provided to support hemophilia management procedures.
Freeline's top competitors include Spark Therapeutics, BridgeBio and Forge Biologics.
Freeline offers FLT201, Gene Therapy for Parkinson's, and Gene Therapy for AMN.
Freeline has made 1 acquisition, including SwanBio Therapeutics.
Freeline has 8 investors. Key investors include Syncona, TD Securities, UCL Technology Fund, Novo Holdings, and Eventide Mutual Funds.